Skip to main contentLast updated: 22-Nov-2026
Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Gastro & Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience
In short
Most colon cancers are adenocarcinomas. The report also gives the grade, the depth, the lymph nodes and the margins, and these decide the plan.
Four tumour tests matter most: MMR or MSI status, RAS, BRAF and HER2. They guide chemotherapy, immunotherapy and targeted drugs.
Ask for these tests early, on the biopsy. Then your surgeon and oncologist can plan one treatment path without delay.
The full plan for surgery and chemotherapy is on our colon cancer treatment page. This post explains what the pathology report says.
It names the type of cancer, how abnormal the cells look, how deep it has grown and whether nodes and margins are clear.
A pathologist studies the biopsy or the removed colon under the microscope. The report is the map your team uses to plan treatment. Two reports matter. The first comes from the biopsy, before surgery. The second comes from the removed colon, after surgery.
The biopsy report confirms cancer and often carries the tumour tests. The surgery report adds the final stage, the lymph node count and the margins. Our post on how colon cancer is staged explains what the T and N letters mean.
Most colon cancers are ordinary adenocarcinomas. A few are mucinous, signet-ring or medullary types, and these behave a little differently.
| Type | What it means for you |
|---|---|
| Adenocarcinoma | Gland-forming cancer. The usual type, and the one most treatment advice is built on. |
| Mucinous adenocarcinoma | Cells float in pools of mucus. More often on the right side, and often linked to MMR loss. |
| Signet-ring cell carcinoma | Uncommon and more aggressive. Can spread along the lining of the belly, so staging needs extra care. |
| Medullary carcinoma | Uncommon, mostly on the right side, almost always MMR deficient. Often behaves better than it looks. |
| Serrated adenocarcinoma | Grows from a serrated polyp. Often carries the BRAF change. |
| Neuroendocrine carcinoma | Rare and fast growing. Treated differently from usual colon cancer. |
Mucinous and signet-ring types are seen a little more often in young Indian patients. If you are young, ask for the MMR test and a careful staging scan.
Grade tells how abnormal the cells look. Budding, vein invasion and nerve invasion show how likely the cancer is to spread or return.
Grade runs from well to poorly differentiated. A poorly differentiated tumour looks less like normal gut tissue. One exception matters. An MMR-deficient tumour can look poorly differentiated and still behave well.
These features are not part of the stage. They still change decisions, especially in stage II disease.
When several of these are present in stage II, your team may advise chemotherapy after surgery. Our post on treatment for stage 1 to 3 colon cancer explains how that decision is made.
MMR testing checks four repair proteins in the tumour. If they are missing, the tumour is called MMR deficient, or MSI-high.
Cells have a spell-check system that repairs copying errors in DNA. In some tumours it is switched off. Such a tumour collects many errors and is easy for the immune system to spot.
The test uses a stain on the biopsy sample. It looks for four proteins called MLH1, MSH2, MSH6 and PMS2. When it is equivocal, a second test called MSI-PCR is done. Every colon cancer should have this test.
| Result | What changes |
|---|---|
| MMR deficient, stage II | Chemotherapy with 5-FU alone is usually not helpful, so it is often skipped. |
| MMR deficient, stage III | Oxaliplatin-based chemotherapy still helps and is usually given. |
| MMR deficient, stage IV | Immunotherapy is usually the first choice, ahead of chemotherapy. |
| MMR deficient, any stage | Possible Lynch syndrome. Genetic testing and family screening may be advised. |
| MMR proficient | Standard chemotherapy plan. Immunotherapy rarely helps in the usual setting. |
Not every MMR-deficient tumour is inherited. Many arise by chance in older people, usually on the right side. A genetic counsellor sorts out which is which. This is the link to our hereditary risk work, and it can matter for your children and brothers and sisters.
These are three tumour changes that decide which targeted drugs can be used when colon cancer has spread. They are tested on the tumour, not the blood.
A few other changes, such as NTRK fusions and KRAS G12C, are rare but have specific drugs. A broad gene panel on the tumour covers all of them in one go.
These tests are mainly for cancer that has spread. Our post on stage 4 colon cancer treatment shows how the results shape the drug choice. In early cancer, MMR is a must, and the other tests are often done at diagnosis so they are ready if the cancer ever returns.
Researchers sorted colon cancer into four consensus molecular subtypes, CMS1 to CMS4, by gene activity. They explain behaviour but do not yet choose treatment.
| Subtype | Main feature |
|---|---|
| CMS1 | MMR deficient, many immune cells, often right-sided and BRAF changed |
| CMS2 | The classic pathway, mostly left-sided, with a good outlook |
| CMS3 | Metabolic type, often with a RAS change |
| CMS4 | Scar-like tissue around the tumour, often advanced, with the poorest outlook |
CMS needs gene activity tests that routine hospital labs do not run. In day-to-day care, the MMR, RAS, BRAF and HER2 results do the work. If a research report mentions a CMS type, this table is a rough guide to it.
They decide whether you need chemotherapy after surgery, whether immunotherapy is a choice, and which targeted drug suits you if the cancer spreads.
Dr Harsh Shah reads the report with the scans before any plan is made. The surgery itself is planned from the scans, the site of the growth and your fitness. The report then adds the drug side of the plan.
If the report does not show MMR status, the node count or the margins, ask the pathologist to review it before any chemotherapy decision.
A complete report gives the site, size, type, grade, depth, margins, node count, invasion findings and MMR status. Missing items should be asked for.
| Item | Why it is needed |
|---|---|
| Type and grade | Tells how the cancer is expected to behave |
| Depth of growth (T) | Part of the stage |
| Margins (cut ends and the deep edge) | Shows if the cancer was fully removed |
| Lymph nodes: number found and number involved | Part of the stage. At least 12 nodes should be examined. |
| Invasion of veins, nerves and tumour deposits | Guides the chemotherapy decision |
| MMR or MSI status | Guides chemotherapy and immunotherapy |
Node counting varies between laboratories. A wider operation that removes the blood supply at its root, called complete mesocolic excision, usually yields more nodes. Your surgeon can ask the laboratory to look for them carefully.
Bring the biopsy and surgery reports, the stained slides or blocks, all scans and any gene test reports. The first visit then lists what is still missing.
Many people have had a biopsy elsewhere. Slides and blocks can be sent to a second laboratory for the MMR and gene tests, so the sample does not need to be taken again. Dr Harsh Shah will go through the report with you in plain words and tell you which tests are still needed. He operates by the laparoscopic or open route, whichever is safer for the person.
It is the pathologist's written findings on the biopsy or the removed colon. It names the cancer type, grade, depth, nodes and margins, and it guides treatment.
The tumour has lost its DNA repair proteins. It can respond very well to immunotherapy, and it may point to an inherited cause such as Lynch syndrome.
Yes. It is a basic test on every colon cancer. It is done on the biopsy and guides chemotherapy, immunotherapy and family screening.
A RAS change means anti-EGFR drugs such as cetuximab will not work. It is checked before these drugs are used for spread cancer.
It is a gene change in some colon cancers. It often goes with a harder-to-treat tumour, and a targeted drug combination is available for it.
Usually it points to a more aggressive cancer. An MMR-deficient tumour can look poorly differentiated yet behave better, so grade is read together with MMR.
Often yes. The stored slides or blocks can be sent for MMR and gene tests, so a fresh biopsy is not always needed.
For surgery and chemotherapy, start at the colon cancer treatment page. For questions before you travel, call +91-63555-64601.
Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601
Got a pathology report that talks about MMR, grade or molecular markers, and unsure what it means? Dr Harsh Shah, a gastro and cancer surgeon in Ahmedabad, explains the terms and how they shape treatment. You can also call us or write on WhatsApp. Call For Appointment Book on WhatsApp Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.
Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.